AmpliMed (Tucson, AZ) a clinical-stage pharmaceutical company with Phase II lead compounds for malignant melanoma and pancreatic cancer closed on $5M traunche of a $22M Series C financing. Participants include BioMed Venture Partners, Biotech Insight Ventures, Solstice Capital and Valley Ventures.